Young Adult Cancer: Influence of the Obesity Pandemic

Obesity

Volumn 26, Issue 4, 2018, Pages 641-650

  Berger, Nathan A ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CARDIA CARCINOMA; COLON CANCER; DISEASE ASSOCIATION; DISEASE COURSE; ENDOMETRIUM CANCER; ESOPHAGEAL ADENOCARCINOMA; EVIDENCE BASED PRACTICE; GALLBLADDER CANCER; HUMAN; KIDNEY CANCER; LIVER CANCER; MALIGNANT NEOPLASM; MENINGIOMA; MORBIDITY; MYELOMA; OBESITY; OVARY CANCER; PANCREAS CANCER; PANDEMIC; RECTUM CANCER; REVIEW; THYROID CANCER; YOUNG ADULT; AGED; COMPLICATION; FEMALE; MALE; MIDDLE AGED; NEOPLASM; PATHOLOGY; RISK; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; OBESITY; RISK;

EID: 85044311346     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.22137     Document Type: Review

References (100)

1. Bleyer A, Barr R, Hayes-Lattin B, Thomas D, Ellis C, Anderson B. The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer 2008;8:288-298.
2. Apovian CM. The obesity epidemic—understanding the disease and the treatment. N Engl J Med 2016;374:177-179.
3. Dietz WH. Obesity and excessive weight gain in young adults: new targets for prevention. JAMA 2017;318:241-242.
4. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-591.
5. Berger NA. Obesity and cancer pathogenesis. Ann N Y Acad Sci 2014;1311:57-76.
6. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body fatness and cancer—viewpoint of the IARC Working Group. N Engl J Med 2016;375:794-798.
7. Cleary MP. Impact of obesity on development and progression of mammary tumors in preclinical models of breast cancer. J Mammary Gland Biol Neoplasia 2013;18:333-343.
8. Doerner SK, Reis ES, Leung ES, et al. High-fat diet-induced complement activation mediates intestinal inflammation and neoplasia, independent of obesity. Mol Cancer Res 2016;14:953-965.
9. Dawson DW, Hertzer K, Moro A, et al. High-fat, high-calorie diet promotes early pancreatic neoplasia in the conditional KrasG12D mouse model. Cancer Prev Res (Phila) 2013;6:1064-1073.
10. Khasawneh J, Schulz MD, Walch A, et al. Inflammation and mitochondrial fatty acid beta-oxidation link obesity to early tumor promotion. Proc Natl Acad Sci U S A 2009;106:3354-3359.
11. Hill-Baskin AE, Markiewski MM, Buchner DA, et al. Diet-induced hepatocellular carcinoma in genetically predisposed mice. Hum Mol Genet 2009;18:2975-2988.
12. Nakagawa H. Recent advances in mouse models of obesity- and nonalcoholic steatohepatitis-associated hepatocarcinogenesis. World J Hepatol 2015;7:2110-2118.
13. Kim T-M, Laird PW, Park PJ. The landscape of microsatellite instability in colorectal and endometrial cancer genomes. Cell 2013;155:858-868.
14. Lwin ST, Olechnowicz SW, Fowler JA, Edwards CM. Diet-induced obesity promotes a myeloma-like condition in vivo. Leukemia 2015;29:507-510.
15. Liu Y, Metzinger MN, Lewellen KA, et al. Obesity contributes to ovarian cancer metastatic success through increased lipogenesis, enhanced vascularity, and decreased infiltration of m1 macrophages. Cancer Res 2015;75:5046-5057.
16. Yu W, Cline M, Maxwell LG, et al. Dietary vitamin D exposure prevents obesity-induced increase in endometrial cancer in Pten+/- mice. Cancer Prev Res (Phila) 2010;3:1246-1258.
17. Quante M, Bhagat G, Abrams JA, et al. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell 2012;21:36-51.
18. Bleyer A, Barr R. Cancer in young adults 20 to 39 years of age: overview. Semin Oncol 2009;36:194-206.
19. American Cancer Society. Cancer Facts and Figures 2017. Atlanta, Georgia: American Cancer Society; 2017.
20. Howlander N, Noone A, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975-2014. Bethesda, MD: National Cancer Institute; 2016. https://seer.cancer.gov/csr/1975_2014/. Published April 2017. Updated June 28, 2017. Accessed September 1, 2017.
21. Arnold M, Pandeya N, Byrnes G, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol 2015;16:36-46.
22. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-170.
23. Jones S, Chen WD, Parmigiani G, et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A 2008;105:4283-4288.
24. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-1113.
25. Cohen AJ, Saiakhova A, Corradin O, et al. Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome. Nat Commun 2017;8:14400. doi: 10.1038/ncomms14400
26. Cohen DH, LeRoith D. Obesity, type 2 diabetes, and cancer: the insulin and IGF connection. Endocr Relat Cancer 2012;19:F27-F45.
27. Karunanithi S, Levi L, DeVecchio J, et al. RBP4-STRA6 pathway drives cancer stem cell maintenance and mediates high-fat diet-induced colon carcinogenesis. Stem Cell Reports 2017;9:438-450.
28. Iyengar NM, Brown KA, Zhou XK, et al. Metabolic obesity, adipose inflammation and elevated breast aromatase in women with normal body mass index. Cancer Prev Res (Phila) 2017;10:235-243.
29. Chang SH, Luo S, Thomas TS, et al. Obesity and the transformation of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based cohort study. J Natl Cancer Inst 2017;109. doi:10.1093/jnci/djw264
30. Kim EJ, Choi M-R, Park H, et al. Dietary fat increases solid tumor growth and metastasis of 4T1 murine mammary carcinoma cells and mortality in obesity-resistant BALB/c mice. Breast Cancer Res 2011;13:R78. doi:10.1186/bcr2927
31. Novosyadlyy R, Leroith D. Insulin-like growth factors and insulin: at the crossroad between tumor development and longevity. J Gerontol A Biol Sci Med Sci. 2012;67:640-651.
32. Zheng Q, Dunlap SM, Zhu J, et al. Leptin deficiency suppresses MMTV-Wnt-1 mammary tumor growth in obese mice and abrogates tumor initiating cell survival. Endocr Relat Cancer 2011;18:491-503.
33. O'Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Rates of colon and rectal cancers are increasing in young adults. Am Surg 2003;69:866-872.
34. Connell LC, Mota JM, Braghiroli MI, Hoff PM. The rising incidence of younger patients with colorectal cancer: questions about screening, biology, and treatment. Curr Treat Options Oncol 2017;18:23. doi:10.1007/s11864-017-0463-3
35. Siegel RL, Jemal A, Ward EM. Increase in incidence of colorectal cancer among young men and women in the United States. Cancer Epidemiol Biomarkers Prev 2009;18:1695-1698.
36. Kim SE, Shim KN, Jung SA, Yoo K, Moon IH. An association between obesity and the prevalence of colonic adenoma according to age and gender. J Gastroenterol 2007;42:616-623.
37. Levi Z, Kark JD, Barchana M, et al. Measured body mass index in adolescence and the incidence of colorectal cancer in a cohort of 1.1 million males. Cancer Epidemiol Biomarkers Prev 2011;20:2524-2531.
38. Kim JY, Jung YS, Park JH, et al. Different risk factors for advanced colorectal neoplasm in young adults. World J Gastroenterol 2016;22:3611-3620.
39. Karanikas M, Esebidis A. Increasing incidence of colon cancer in patients <50 years old: a new entity? Ann Transl Med 2016;4:164. doi:10.21037/atm.2016.04.13
40. You YN, Xing Y, Feig BW, Chang GJ, Cormier JN. Young-onset colorectal cancer: is it time to pay attention? Arch Intern Med 2012;172:287-289.
41. Bailey CE, Hu CY, You YN, et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg 2015;150:17-22.
42. Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin 2017;67:177-193.
43. Le Marchand L, Wilkens LR, Mi MP. Obesity in youth and middle age and risk of colorectal cancer in men. Cancer Causes Control 1992;3:349-354.
44. Ortiz AP, Thompson CL, Chak A, Berger NA, Li L. Insulin resistance, central obesity, and risk of colorectal adenomas. Cancer 2012;118:1774-1781.
45. Atkin W, Wooldrage K, Brenner A, et al. Adenoma surveillance and colorectal cancer incidence: a retrospective, multicentre, cohort study. Lancet Oncol 2017;18:823-834.
46. Grahn SW, Varma MG. Factors that increase risk of colon polyps. Clin Colon Rectal Surg 2008;21:247-255.
47. Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 2009;22:191-197.
48. Hahn MM, de Voer RM, Hoogerbrugge N, Ligtenberg MJ, Kuiper RP, van Kessel AG. The genetic heterogeneity of colorectal cancer predisposition - guidelines for gene discovery. Cell Oncol (Dordr) 2016;39:491-510.
49. van Duijnhoven FJ, Botma A, Winkels R, Nagengast FM, Vasen HF, Kampman E. Do lifestyle factors influence colorectal cancer risk in Lynch syndrome? Fam Cancer 2013;12:285-293.
50. Mork ME, You YN, Ying J, et al. High prevalence of hereditary cancer syndromes in adolescents and young adults with colorectal cancer. J Clin Oncol 2015;33:3544-3549.
51. Movahedi M, Bishop DT, Macrae F, et al. Obesity, aspirin, and risk of colorectal cancer in carriers of hereditary colorectal cancer: a prospective investigation in the CAPP2 Study. J Clin Oncol 2015;33:3591-3597.
52. Anders CK, Johnson R, Litton J, Phillips M, Bleyer A. Breast cancer before age 40 years. Semin Oncol 2009;36:237-249.
53. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993;15:17-35.
54. Cecchini RS, Costantino JP, Cauley JA, et al. Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials. Cancer Prev Res (Phila) 2012;5:583. doi: 10.1158/1940-6207.CAPR-11-0482
55. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010;363:1938-1948.
56. Sturtz LA, Melley J, Mamula K, Shriver CD, Ellsworth RE. Outcome disparities in African American women with triple negative breast cancer: a comparison of epidemiological and molecular factors between African American and Caucasian women with triple negative breast cancer. BMC Cancer 2014;14:62. doi:10.1186/1471-2407-14-62
57. Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med 2010;12:245-59.
58. Guindalini RS, Song A, Fackenthal JD, Olopade OI, Huo D. Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect. Cancer 2016;122:1913-1920.
59. Kotsopoulos J, Olopado OI, Ghadirian P, et al. Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 2005;7:R833-R843.
60. Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst 2010;102:170-178.
61. Taccoen X, Valeri A, Descotes JL, et al. Renal cell carcinoma in adults 40 years old or less: young age is an independent prognostic factor for cancer-specific survival. Eur Urol 2007;51:980-987.
62. Albiges L, Hakimi AA, Xie W, et al. Body mass index and metastatic renal cell carcinoma: clinical and biological correlations [published online September 6, 2016]. J Clin Oncol doi:10.1200/JCO.2016.66.7311
63. Beebe-Dimmer JL, Colt JS, Ruterbusch JJ, et al. Body mass index and renal cell cancer: the influence of race and sex. Epidemiology 2012;23:821-828.
64. Garg K, Soslow RA. Endometrial carcinoma in women aged 40 years and younger. Arch Pathol Lab Med 2014;138:335-342.
65. Ying AK, Huh W, Bottomley S, Evans DB, Waguespack SG. Thyroid cancer in young adults. Semin Oncol 2009;36:258-274.
66. Borges AKdM, Miranda-Filho A, Koifman S, Koifman RJ. Thyroid cancer incidences from selected South America population-based cancer registries: an age-period-cohort study. J Global Oncol 2018;4:1-11.
67. Li D, Morris JS, Liu J, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 2009;301:2553-2562.
68. National Cancer Intelligence Network. Is pancreatic cancer becoming more common in the young? NCIN Data Briefing. 2011. www.ncin.org.uk/databriefings. Accessed October 4, 2017.
69. Tingstedt B, Weitkamper C, Andersson R. Early onset pancreatic cancer: a controlled trial. Ann Gastroenterol 2011;24:206-212.
70. Kew MC. Hepatocellular carcinoma: epidemiology and risk factors. J Hepatocell Carcinoma 2014;1:115-125.
71. Campbell PT, Newton CC, Freedman ND, et al. Body mass index, waist circumference, diabetes, and risk of liver cancer for U.S. adults. Cancer Res 2016;76:6076-6083.
72. Yu J, Shen J, Sun TT, Zhang X, Wong N. Obesity, insulin resistance, NASH and hepatocellular carcinoma. Semin Cancer Biol 2013;23(6 Pt B):483-491.
73. Petrick JL, Kelly SP, Liao LM, Freedman ND, Graubard BI, Cook MB. Body weight trajectories and risk of oesophageal and gastric cardia adenocarcinomas: a pooled analysis of NIH-AARP and PLCO Studies. Br J Cancer 2017;116:951-959.
74. Doycheva I, Watt KD, Alkhouri N. Nonalcoholic fatty liver disease in adolescents and young adults: the next frontier in the epidemic. Hepatology 2017;65:2100-2109.
75. Carson KR, Bates ML, Tomasson MH. The skinny on obesity and plasma cell myeloma: a review of the literature. Bone Marrow Transplant 2014;49:1009-1015.
76. Blade J, Kyle RA. Multiple myeloma in young patients: clinical presentation and treatment approach. Leuk Lymphoma 1998;30:493-501.
77. Yanamandra U, Saini N, Chauhan P, et al. AYA-myeloma: real-world, single-center experience over last 5 years. J Adolesc Young Adult Oncol 2018;7:120-124.
78. Birmann BM, Andreotti G, De Roos AJ, et al. Young adult and usual adult body mass index and multiple myeloma risk: a pooled analysis in the International Multiple Myeloma Consortium (IMMC). Cancer Epidemiol Biomarkers Prev 2017;26:876-885.
79. Sagaster V, Kaufmann H, Odelga V, et al. Chromosomal abnormalities of young multiple myeloma patients (<45 yr) are not different from those of other age groups and are independent of stage according to the International Staging System. Eur J Haematol 2007;78:227-234.
80. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354:1362-1369.
81. Dhodapkar MV. MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood 2016;128:2599-2606.
82. Therneau TM, Kyle RA, Melton LJ, 3rd, et al. Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. Mayo Clin Proc 2012;87:1071-1079.
83. Landgren O, Rajkumar SV, Pfeiffer RM, et al. Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood 2010;116:1056-1059.
84. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999;26(5 suppl 15):2-8.
85. Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993;104:510-513.
86. Oezcelik A, Ayazi S, DeMeester SR, et al. Adenocarcinoma of the esophagus in the young. J Gastrointest Surgery 2013;17:1032-1035.
87. Runge TM, Abrams JA, Shaheen NJ. Epidemiology of Barrett's esophagus and esophageal adenocarcinoma. Gastroenterol Clin North Am 2015;44:203-231.
88. Portale G, Peters JH, Hsieh CC, et al. Esophageal adenocarcinoma in patients < or = 50 years old: delayed diagnosis and advanced disease at presentation. Am Surg 2004;70:954-958.
89. Shao C, Bai LP, Qi ZY, Hui GZ, Wang Z. Overweight, obesity and meningioma risk: a meta-analysis. PLoS One 2014;9:e90167. doi:10.1371/journal.pone.0090167
90. Prabhu VC, Perry EC, Melian E, Barton K, Guo R, Anderson DE. Intracranial meningiomas in individuals under the age of 30; Analysis of risk factors, histopathology, and recurrence rate. Neuroscience Discovery 2014;2. doi:10.7243/2052-6946-2-1
91. Brokaw J, Katsaros D, Wiley A, et al. IGF-I in epithelial ovarian cancer and its role in disease progression. Growth Factors. 2007;25:346-354.
92. Cancer Research UK website. Gallbladder cancer incidence statistics. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/gallbladder-cancer/incidence#heading-One. Accessed October 18, 2017. Updated January 24, 2018.
93. Castro FA, Koshiol J, Hsing AW, Devesa SS. Biliary tract cancer incidence in the United States-Demographic and temporal variations by anatomic site. Int J Cancer 2013;133:1664-1671.
94. Ezzati MN-RC. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet 2016;387:1377-1396.
95. Afshin A, Forouzanfar MH, Reitsma MB, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med 2017;377:13-27.
96. Higurashi T, Hosono K, Takahashi H, et al. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol 2016;17:475-483.
97. Rossi EL, de Angel RE, Bowers LW, et al. Obesity-associated alterations in inflammation, epigenetics, and mammary tumor growth persist in formerly obese mice. Cancer Prev Res (Phila) 2016;9:339-348.
98. Jones PA, Issa JP, Baylin S. Targeting the cancer epigenome for therapy. Nat Rev Genet 2016;17:630-641.
99. Moinova H, Leidner RS, Ravi L, et al. Aberrant vimentin methylation is characteristic of upper gastrointestinal pathologies. Cancer Epidemiol Biomarkers Prev 2012;21:594-600.
100. Friedrich MJ. Going with the flow: the promise and challenge of liquid biopsies. JAMA 2017;318:1095-1097.